Barely Significant
← all phrases

“showed a trend”

53,323 sentences · 53,323 papers · 65,371 search hits before verification

In the literature

A double-blind, randomized, placebo-controlled clinical trial with a parallel-group design involving 26 MS patients treated with interferon beta (13 of them receiving a supplement of melatonin and the other 13 receiving placebo) with 1-year of follow-up showed a lack of beneficial effect of melatonin on the number of relapses, EDSS, appearance of new lesions in magnetic resonance imaging (MRI), fatigue and depression, although patients under melatonin showed a trend towards improvement in the performance of Multiple Sclerosis Functional Scale [ 54 ].
showed a trend favoring endovascular therapy (EVT) over medical therapy alone in managing IIAs over the last decade, attributed to advancements in neuroendovascular techniques and tools.[ 1 ] This approach has been associated with higher treatment success rates and lower mortality.[ 1 ] However, despite the favorable trend toward EVT, data on the safety and efficacy of these interventions primarily come from smaller case series and reports, with no randomized controlled trials establishing a standard of care.
The curves showed a trend of decreasing hearing thresholds with increasing α-Klotho levels, but no non-linear relationship was observed. 3.4 Hearing loss risk assessment Table 4 presents adjusted odds ratios ( OR s) and their 95% confidence intervals ( CI s) for the relationship between serum α-Klotho levels and hearing loss in the study population.
However, most studies showed a trend toward survival benefits in the CRT+S group, except for one study. 38 Only one study showed significant survival benefits in the CRT+S group. 32 Controversies of Clinical Issues Indications In the NCCN guidelines, surveillance is recommended for clinical T1-2N0M0 EC patients with negative margins (R0 resection) after radical surgery regardless of the pathological stage (p Any T, Any N) and CRT+S is recommended for patients with resectable clinical T3-4N0M0 or T1-4N+M0 diseases.